Project cooperationUpdated on 15 January 2026
Expertise offer: synthetic chemistry and process development
Research Programme Manager at KelAda Pharmachem
DUBLIN, Ireland
About
KelAda Pharmachem Ltd is a research-intensive Irish SME pioneering the development of high-value chemical compounds through innovative, sustainable chemistry. Our mission is to catalyse the integration of green chemistry technologies into the manufacture of pharmaceutical ingredients, nutraceuticals, and fine chemicals, with a strong focus on solutions that improve human health.
KelAda leverages deep expertise in synthetic chemistry and process development, enabling the design and optimisation of scalable chemical processes for bioactive compounds. We specialise in transforming challenging starting materials into high-value products, ensuring that the processes are both efficient and sustainable, in line with the European Green Deal and Horizon Europe objectives.
Our capabilities are directly relevant to Cluster 1 priorities, including:
-
Development of innovative therapies and bioactive compounds: using advanced chemistry to create molecules with potential therapeutic, preventive, or diagnostic applications.
-
Sustainable and scalable production: integrating green and scalable chemical processes into the manufacturing of health-relevant compounds.
-
Advanced process development and validation: enabling robust translation of research outputs into real-world applications, supporting regulatory compliance and industrial feasibility.
-
Collaborative R&I projects: as an experienced partner and coordinator of large-scale European consortia, KelAda can contribute both leadership and technical expertise to multi-partner projects, ensuring the efficient valorisation and integration of chemical innovation into final products.
KelAda is ideally positioned to contribute to Horizon Europe Cluster 1 calls that target novel therapeutic agents, innovative manufacturing of medicines, and sustainable health solutions, bringing both cutting-edge chemistry expertise and process development experience to collaborative projects aiming to improve human health in an innovative and scalable manner.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
Algae-Derived Biopolymers for Health, Nutrition & Bioactive Formulations
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Stefano Todde
Project Specialist at PMO Partners
IStanbul, Türkiye
Project cooperation
Synthetic & CADD Labs – Design, Synthesis and Extraction of Bioactive Compounds
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Antonio Lupia
Researcher - RTDA at University of Cagliari (UNICA)
Cagliari, Italy
Project cooperation
Medicinal Chemistry & Drug Discovery for Infectious and Neurodegenerative Diseases
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Ioanna Kalograiaki
Internationalization Research Manager at Centro de Investigaciones Biológicas Margarita Salas-CSIC
Madrid, Spain